Nextcure, Inc. (NXTC) Stock Price & Analysis

Nextcure, Inc. (NXTC) fell 0.26% to USD 7.82 as of September 8, 2026 at 07:36 UTC, according to Nexqual real-time market data.

NXTC last closed at USD 7.82; the session ranged USD 7.6–8.23 on volume of 60,631 shares. Market capitalization is —, with a 52-week range of USD 1.55–15.74 (NMS). Source: Nexqual, September 8, 2026 at 07:36 UTC.

Key Statistics (as of September 8, 2026 at 07:36 UTC)

Technical Analysis (NXTC)

Nexqual's technical model rates NXTC "BUY" based on 5 bullish and 1 bearish signals across 128 daily candles, as of September 8, 2026 at 07:36 UTC.

From Nextcure, Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)

Key Strengths & Strategy (as disclosed to the SEC)

• Payload – A proprietary novel TOPO1 inhibitor known as CPT116, with a drug-to-antibody ratio (DAR) of 8, has demonstrated high systemic clearance for reduced toxicity due to its hydrophilic properties. 7 Table of Contents In December 2024, Zaiming received FDA clearance for its IND for a Phase 1 clinical trial to treat multiple cancers.
• We seek to protect our proprietary technology and processes, in part, by confidentiality and invention assignment agreements with our employees, consultants, scientific advisors and other contractors.
• Review and Approval for Licensing Biologics in the United States In the United States, the FDA regulates our current product candidates as biological products, or biologics, under the Federal Food, Drug, and Cosmetic Act, or "FDCA", the Public Health Service Act and associated implementing regulations.
• The FDA may also require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess the drug's safety after approval.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 07:36 UTC. This page is informational and not investment advice.